Straits Times Index
3,245.97 +9.89 (+0.31%) Nikkei
27,901.01 +326.58 (+1.18%) Hang Seng
19,900.87 +450.64 (+2.32%) FTSE 100
7,476.63 +4.46 (+0.06%) BTC-USD
17,146.52 -75.48 (-0.44%) CMC Crypto 200
402.11 -4.14 (-1.02%)
Precision BioSciences, Inc. (DTIL)
After hours:
| Previous close | 1.1600 |
| Open | 1.1600 |
| Bid | 1.1800 x 1800 |
| Ask | 1.1900 x 900 |
| Day's range | 1.1500 - 1.2500 |
| 52-week range | 1.1000 - 8.8100 |
| Volume | |
| Avg. volume | 682,677 |
| Market cap | 132.041M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings date | 08 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.33 |
- Business Wire
Precision BioSciences Announces Change to its Board of Directors
DURHAM, N.C., November 10, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. Raymond Schinazi is stepping down from the company’s Board of Directors and will continue as a member of the company’s SAB, lending his deep expertise in antiviral drug discovery and development.
- Zacks
Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
DURHAM, N.C., November 08, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
